NewsBenzingaPS International Group: utile per azione H1 EPS a $(0,71), in calo rispetto a $(0,13) su base annua; vendite a 26,534 milioni di dollari, in aumento rispetto a 23,188 milioni di dollari su base annua. PS International Group: utile per azione H1 EPS a $(0,71), in calo rispetto a $(0,13) su base annua; vendite a 26,534 milioni di dollari, in aumento rispetto a 23,188 milioni di dollari su base annua. Benzinga 2026.11.03 16:32 (GMT+0) Open on Benzinga Other news Coinbase CEO Wants AI Agents to Hire and Pay Each Other In Decentralized Economy: 'Freedom of Choice and Real Competition' Nvidia, Target and 3 Stocks to Watch Heading Into Wednesday 'Grand Theft Auto VI Is a Masterpiece; It turns out that the secret ingredients to a great game are a lot of money, time and talented people' - Bloomberg Summit Therapeutics Initiates Global Phase III Clinical Trial Of Ivonescimab In Non-Small Cell Lung Cancer; Expects Global Clinical Trial Site Activations For HARMONi-10 To Begin In Q4 2026 Jim Farley Says ‘Bronco to the Rescue’ As Woman Stranded by FAA Ground Stop Buys Ford SUV for 1,600-Mile Journey Home Recursion Has Aligned With the FDA on Its Registrational Phase 3 Trial of Rec-4881 for Familial Adenomatous Polyposis; Trial on Track to Begin in 2H of 2027
Coinbase CEO Wants AI Agents to Hire and Pay Each Other In Decentralized Economy: 'Freedom of Choice and Real Competition'
'Grand Theft Auto VI Is a Masterpiece; It turns out that the secret ingredients to a great game are a lot of money, time and talented people' - Bloomberg
Summit Therapeutics Initiates Global Phase III Clinical Trial Of Ivonescimab In Non-Small Cell Lung Cancer; Expects Global Clinical Trial Site Activations For HARMONi-10 To Begin In Q4 2026
Jim Farley Says ‘Bronco to the Rescue’ As Woman Stranded by FAA Ground Stop Buys Ford SUV for 1,600-Mile Journey Home
Recursion Has Aligned With the FDA on Its Registrational Phase 3 Trial of Rec-4881 for Familial Adenomatous Polyposis; Trial on Track to Begin in 2H of 2027